Monday, March 9, 2026
Written By Param Malik, Editor-in-Chief
The FDA’s "Reform Era" has just lost its chief architect. With the sudden departure of Vinay Prasad, the industry is left wondering if the agency’s pivot toward evidence-based stringency was a permanent structural shift or a temporary academic exercise. Meanwhile, the M&A market is proving that pediatric oncology is the new high-margin battleground, and Senate Democrats are finally pulling the curtain back on the White House's "Secret Deals."
The signals are louder than ever.
Let’s dive in.
Last Week in Biotech, Pharma & Finance
The Prasad Exit: Vinay Prasad, the controversial head of the FDA’s Center for Biologics (CBER) and a key ally of Commissioner Marty Makary, is leaving the agency at the end of April. Officially, it’s the end of a one-year academic leave from UCSF; unofficially, it follows a week of intense heat over his public criticism of uniQure’s "distorted" data. His departure leaves the FDA’s new "2-to-1" pivotal trial standard and the ultra-rare disease framework in a state of leadership flux.
Servier’s $2.5B Pediatric Bet: French pharma giant Servier is acquiring Day One Biopharmaceuticals for $2.5 billion in cash. The prize is Ojemda, an FDA-approved therapy for pediatric low-grade glioma. By pairing Ojemda with their existing Voranigo asset, Servier is effectively cornering the market on targeted glioma therapies. It’s a clear signal: specialized pediatric oncology is no longer a "niche"—it’s a cornerstone for M&A.
The Democrats’ Demand: Senate Finance Chair Ron Wyden and six other Democrats have officially pressed 11 major drugmakers—including AbbVie, Gilead, and Merck—for evidence that their TrumpRx pricing deals actually save Medicaid any money. The letters suggest the "secret deals" might be shielding brand-name drugs from generic competition without delivering net savings to taxpayers.
Sanofi’s Brazilian Exit: Continuing its "Play to Win" strategy, Sanofi has agreed to sell its Medley generics unit in Brazil to local leader EMS. Sanofi is shedding low-margin legacy assets to fund high-growth R&D, much like the recent spin-off of its consumer health business (Opella).
J&J’s Speed Record: In a win for the administration’s "National Priority" initiative, the FDA granted a third approval under the program to J&J’s Tecvayli-Darzalex combo for multiple myeloma. The turnaround time for this combo was significantly faster than standard reviews, proving the new "Voucher" system is working for the majors.
SCOTUS vs. Tariffs: The Supreme Court struck down the administration’s emergency global tariffs. The ruling specifically invalidates levies deployed under the IEEPA (International Emergency Economic Powers Act), though industry-specific Section 232 probes remain in play. The immediate fallout? A sharp presidential rebuke and a promise to pivot to a new 10% global tariff mechanism. For pharma, the question is leverage: without the immediate threat of IEEPA tariffs, will the "voluntary" $600B investment pledges from the top 17 drugmakers remain on track?
New FDA drug approvals?
This Week: Yes.
Tecvayli (teclistamab) + Darzalex: Approved on 3/5/2026 for relapsed or refractory multiple myeloma. This marks a major milestone for bispecific antibodies moving into earlier lines of therapy.
Zongertinib: Granted accelerated approval (late Feb) for non-squamous NSCLC, reinforcing the trend of fast-tracked oncology nods.
The Latest from Healthcare Insights
Here's what we're writing about at healthcarein.org:
What’s on Our Mind for the Next Two Weeks
The "Trade Secret" Tightrope The accusation that Vinay Prasad leaked "trade secrets" about uniQure’s failed Huntington’s trial has put the industry on high alert. We’re thinking about the limits of FDA transparency. How much can the regulator share before they destroy a company’s market cap—and where is the legal line?
Today (March 9): The New ACIP Paradigm With RFK Jr.’s handpicked panel set to meet, we are preparing for a fundamental shift in how the CDC recommends—and insurers cover—immunizations. Any move to de-list or re-categorize major vaccines will trigger immediate ripples in the public health capital flows we’ve been tracking.
The Week Ahead
March 9–12: HIMSS Global Health Conference (Las Vegas). All eyes are on AI data governance and the "Digital Twin" revolution in drug discovery.
March 9: Phio Pharmaceuticals (PHIO) hosts a live Virtual Roadshow. Watch for updates on their INTASYL platform.
March 12: Nextech EDGE 2026. A key event for those tracking the digital transformation of specialty workflows.
PDUFA Watch: Expect the first ripples from the Takeda/Protagonist Priority Review for rusfertide (Polycythemia Vera) as the agency begins its internal assessment.
Takeaways
The narrative this week is consolidation and clarification. Servier is consolidating pediatric cancer; Sanofi is consolidating its R&D focus; and the Senate is finally demanding clarification on the drug pricing "deals" that have governed 2026 so far. With the primary skeptic (Prasad) leaving the FDA, the ball is back in the pharmaceutical industry's court to prove that "flexible" regulation leads to better outcomes, not just higher volumes.
Stay curious, stay sharp, and we will see you in seven days.
With gratitude and resolve,
The Healthcare Insights Team
Reach out to us by email at [email protected].
